Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation-positive NSCLC: An interim analysis of the ARIA study

被引：0
|
作者：
Wu, L. [1 ,2 ]
Li, J. [3 ]
Xu, C. [4 ,5 ]
Biswas, B. [6 ]
Tang, K. [7 ]
Wang, H. [8 ,9 ]
Liu, Z. [10 ]
Batra, U. [11 ]
Ho, G. F. [12 ]
Low, S. H. J. [13 ]
Lu, Y. [14 ]
Zhao, M. [15 ]
Tho, L. M. [16 ]
Zhao, J. [17 ]
He, S. [18 ]
Huang, J. [19 ]
Tang, X. [20 ]
Wong, C. H. [21 ]
Wu, Y-L. [4 ,5 ]
机构：
[1] Cent South Univ, Dept Med Oncol, Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, China Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[4] Guangdong Prov Peoples Hosp, Lung Canc Inst, Guangzhou, Peoples R China
[5] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India
[7] Sun Yat Sen Univ, Resp & Crit Care Med Dept, Affiliated Hosp 1, Guangzhou, Peoples R China
[8] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] First Hosp Jilin Univ, Dept Oncol Ctr, Changchun, Peoples R China
[11] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India
[12] Univ Malaya, Dept Clin Oncol, Med Ctr, Kuala Lumpur, Malaysia
[13] Pantai Hosp, Oncol & Radiotherapy, Kuala Lumpur, Malaysia
[14] Sichuan Univ, West China Sch Clin Med, West China Hosp, Oncol, Chengdu, Peoples R China
[15] China Med Univ, Dept Oncol, Hosp 1, Shenyang, Peoples R China
[16] Beacon Hosp, Dept Clin Oncol, Petaling Jaya, Malaysia
[17] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Thorac Oncol, Minist Educ, Beijing, Peoples R China
[18] Pfizer Inc, Clin Dev, Shanghai, Peoples R China
[19] Pfizer China Res & Dev Co Ltd, Clin Data Qual Dev China, Shanghai, Peoples R China
[20] Pfizer Inc, Pfizer GB & DM, CHN Stat, Shanghai, Peoples R China
[21] Pfizer Pte Ltd, Med Affairs, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2370
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1337P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
  • [22] EGFR Mutation Subtypes Influence Survival Outcomes' following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
    Sutiman, Natalia
    Weng, Shao
    Tan, Eng Huat
    Lim, Wan Teck
    Kanesvaran, Ravindran
    Ng, Quan Sing
    Jain, Amit
    Ang, Mei Kim
    Tan, Wan Ling
    Toh, Chee Keong
    Chowbay, Balram
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (03) : 529 - 538
  • [23] Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
    Lee, J. Y.
    Mai, V.
    Garcia, M.
    Cheng, S.
    Khan, K.
    Balaratnam, K.
    Thakral, A.
    Brown, M. C.
    Zhan, L.
    Corke, L.
    Leighl, N.
    Shepherd, F. A.
    Bradbury, P.
    Sacher, A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S440 - S440
  • [24] Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
    Gautam, S.
    Herms, L.
    Bartolome, L.
    Pastel, M.
    Wilner, K.
    Fisher, M.
    Ivanova, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S618 - S619
  • [25] Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China
    Ji, W.
    Li, X.
    Cang, S.
    Xiang, Y.
    Li, X.
    Zhang, J.
    Tan, J.
    Wang, Q.
    Jiang, D.
    Zhang, H.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [26] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
    Fang, S.
    Xu, T.
    Zhao, X.
    Liu, N.
    Wang, X.
    Cheng, W.
    Fang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
  • [27] Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States
    Samuelsen, Carl
    Lim, Jonathan
    Golembesky, Amanda
    Shrestha, Sulena
    Wang, Li
    Griebsch, Ingolf
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 48 - 53
  • [28] Real-World Management and Outcomes of Uncommon EGFR Mutation-Positive NSCLC Patients at Two Tertiary Canadian Cancer Centres
    Tudor, R.
    Gibson, A.
    Hao, F.
    Dean, M.
    Kopciuk, K.
    Bebb, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S839 - S840
  • [29] ARCHER 1050: first-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s)
    Nakagawa, Kazuhiko
    Mok, Tony S. K.
    Wu, Yi-Long
    Rosell, Rafael
    Tsuji, Fumito
    Wang, Tao
    Sbar, Eric
    ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
  • [30] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
12345